Cue Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cue Biopharma, Inc. (Nasdaq: CUE) on June 2, 2026, covering events occurring between May 29, 2026, and June 1, 2026. The filing details significant changes to the Company's Board of Directors and executive leadership team.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
- Board Resignations: On May 29, 2026, Jill Broadfoot, Peter Kiener, Frank Morich, and Patrick Verheyen resigned from the Board of Directors and all associated committees effective immediately. The resignations were mutual and not due to any disagreement with the Company.
- Board Reduction: The Board size was reduced from seven directors to five directors, effective June 1, 2026.
- New Director Appointments: On May 30, 2026, Daniel Camardo and Viola Meehan were appointed as directors for one-year terms.
- Executive Appointments:
- Sumita Ray, JD, was appointed Chief Legal & Compliance Officer and Corporate Secretary, effective June 1, 2026, succeeding Colin Sandercock, who will remain as Senior Vice President, Intellectual Property.
- Michael Meluzio was appointed Vice President, Principal Accounting Officer, effective June 1, 2026, superseding his prior role as Vice President, Finance.
- Committee Restructuring:
- Audit Committee: Chaired by Viola Meehan; members include Daniel Camardo and Pamela Garzone.
- Compensation Committee: Chaired by Pamela Garzone; members include Daniel Camardo and Viola Meehan.
- Nominating and Corporate Governance Committee: Chaired by Daniel Camardo; members include Pasha Sarraf and Pamela Garzone.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. The primary risk disclosed relates to the indemnification agreements entered into with new directors Mr. Camardo and Ms. Meehan, under which the Company may be required to indemnify them for certain expenses, judgments, penalties, fines, and settlement amounts arising from their service.
Investor Verification Checklist
- Verify the specific compensation packages for new directors Daniel Camardo and Viola Meehan as outlined in the 2026 Proxy Statement.
- Confirm the transition timeline for Colin Sandercock's departure from the General Counsel role and Sumita Ray's onboarding.
- Review the Company's 2025 Form 10-K for the full text of the Director Compensation Policy and standard indemnification agreements.
- Assess the impact of the reduced Board size (from 7 to 5) on corporate governance oversight.